Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity

Background: Type 2 diabetes mellitus (DM2), which mainly develops from visceral obesity, is a socially significant disease. Reduction of losses from DM2 is a priority in modern medicine development. Glucagon-like peptide-1 receptor agonists (aGLP-1) present one of few groups of antidiabetic drugs th...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ekaterina V. Tikhonenko, Alina Y. Babenko, Evgeny V. Shlyakhto
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrinology Research Centre 2018-12-01
Серии:Ожирение и метаболизм
Предметы:
diabetes type 2
obesity
glucagon-like peptide-1 receptor agonists
glucagon-like peptide-1
ghrelin
food behavior
Online-ссылка:https://www.omet-endojournals.ru/jour/article/view/9584
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы